Washington Capital Management Inc. held its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,090 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Bristol-Myers Squibb accounts for about 2.6% of Washington Capital Management Inc.’s investment portfolio, making the stock its 11th biggest position. Washington Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $2,290,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. State Street Corp increased its holdings in Bristol-Myers Squibb by 1.8% in the 1st quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after acquiring an additional 1,223,457 shares in the last quarter. Jennison Associates LLC increased its holdings in Bristol-Myers Squibb by 0.8% in the 1st quarter. Jennison Associates LLC now owns 21,927,898 shares of the biopharmaceutical company’s stock worth $1,192,439,000 after acquiring an additional 178,436 shares in the last quarter. Ameriprise Financial Inc. increased its holdings in Bristol-Myers Squibb by 18.7% in the 1st quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after acquiring an additional 2,451,390 shares in the last quarter. Legal & General Group Plc increased its holdings in Bristol-Myers Squibb by 4.3% in the 1st quarter. Legal & General Group Plc now owns 8,213,428 shares of the biopharmaceutical company’s stock worth $446,664,000 after acquiring an additional 335,795 shares in the last quarter. Finally, Swiss National Bank increased its holdings in Bristol-Myers Squibb by 27.2% in the 1st quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock worth $322,020,000 after acquiring an additional 1,267,900 shares in the last quarter. 68.87% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts recently issued reports on BMY shares. Cowen and Company reissued a “hold” rating and issued a $65.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday, September 19th. Jefferies Group LLC increased their target price on shares of Bristol-Myers Squibb from $66.00 to $72.00 and gave the stock a “buy” rating in a report on Monday, September 11th. Vetr lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 target price for the company. in a report on Thursday, September 28th. UBS AG reissued a “buy” rating and issued a $72.00 target price (up from $62.00) on shares of Bristol-Myers Squibb in a report on Friday, October 6th. Finally, Hilliard Lyons lowered shares of Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 target price for the company. in a report on Tuesday, September 12th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company. Bristol-Myers Squibb currently has a consensus rating of “Buy” and an average target price of $62.71.
Shares of Bristol-Myers Squibb Company (NYSE BMY) opened at 65.11 on Thursday. The company has a 50-day moving average price of $62.24 and a 200-day moving average price of $56.84. Bristol-Myers Squibb Company has a 12 month low of $46.01 and a 12 month high of $65.50. The company has a market capitalization of $106.78 billion, a P/E ratio of 23.78 and a beta of 1.19.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The company had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm’s quarterly revenue was up 5.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.69 EPS. On average, analysts forecast that Bristol-Myers Squibb Company will post $2.98 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th will be paid a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 2.40%. The ex-dividend date of this dividend is Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 56.73%.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://sportsperspectives.com/2017/10/12/bristol-myers-squibb-company-bmy-stake-maintained-by-washington-capital-management-inc.html.
In other news, SVP Joseph C. Caldarella sold 9,340 shares of the company’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the transaction, the senior vice president now owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Theodore R. Samuels II purchased 6,000 shares of the firm’s stock in a transaction dated Wednesday, August 2nd. The stock was acquired at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the purchase, the director now owns 18,000 shares in the company, valued at $1,006,920. The disclosure for this purchase can be found here. Corporate insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.